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Abstract
Background: There is great overlap between the presentation
of cachexia, sarcopenia, and malnutrition. Distinguishing between
these conditions would allow for better targeted treatment for
patients.
Objectives: The aim was to systematically review validated
screening tools for cachexia, sarcopenia, and malnutrition in adults
and, if a combined tool is absent, make suggestions for the generation
of a novel screening tool.
Design: A systematic search was performed in Ovid Medline,
EMBASE, CINAHL, and Web of Science. Two reviewers performed
data extraction independently. Each tool was judged for validity
against a reference method. Psychometric evaluation was performed
as was appraisal of the tools’ ability to assess the patient against
consensus definitions.
Results: Thirty-eight studies described 22 validated screening tools.
The Cachexia score was the only validated screening tool for
cachexia and performed well against the consensus definition.
Two tools assessed sarcopenia [the Short Portable Sarcopenia
Measure (SPSM) and the SARC-F] and scored well against the
1998 Baumgartner definition. The SPSM required large amounts
of equipment, and the SARC-F had a low sensitivity. Nineteen
tools screened for malnutrition. The 3-Minute Nutrition Score
performed best, meeting consensus definition criteria (European
Society for Clinical Nutrition and Metabolism) and having a
sensitivity and specificity of >80%. No tool contained all of
the currently accepted components to screen for all 3 conditions.
Only 3 tools were measured against cross-sectional imaging, a
clinical tool that is gaining wider interest in body-composition
analysis.
Conclusions:No single validated screening tool can be implemented
for the simultaneous assessment of cachexia, sarcopenia, and
malnutrition. The development of a tool that encompasses consensus
definition criteria and directs clinicians toward the underlying
diagnosis would be optimal to target treatment and improve
outcomes. We propose that tool should incorporate a stepwise
assessment of nutritional status–oral intake, disease status, age,
musclemass and function, andmetabolic derangement. AmJClin
Nutr 2018;108:1–13.
Keywords: cachexia, sarcopenia, malnutrition, screening, assess-
ment
INTRODUCTION
Unintentional weight loss (UWL) as a form of nutritional
depletion is commonly seen in aging, cancer, and many chronic
diseases. The main subtypes can be categorized into 3 primary
syndromes: cachexia, age-related sarcopenia, and malnutrition.
However, it is not clear whether existing screening tools are
able to distinguish between these 3 conditions. This is due in
part to the complex overlap between them. Loss of muscle mass
is a key feature in both cachexia and sarcopenia, but patients
with sarcopenia are not necessarily cachectic. Sarcopenia can
occur simply with aging and leads to functional decline (1,
2). Cachexia involves complex metabolic pathways leading to
systemic inflammation and muscle and fat wasting and must
be present in association with a chronic disease (3). Cachexia
differs from malnutrition in that it cannot be reversed by simple
nutritional support (4). There are many definitions for each
condition, with nutritional depletion playing a part in each,
therefore making it difficult to separate them out (1–4). These
conditions are also often not noticed in their earlier phases but
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do become apparent after a critical event or development of
disability (5).
More than 70 nutritional screening tools for use in hospitals
have been developed to facilitate easy screening or assessment of
a patient’s nutritional status or to predict poor clinical outcome
related to UWL. Despite increasing research, there appears to
be a lack of a practical and implementable clinical screening
tool to support diagnosis (6). In the general community, the
European Society for Clinical Nutrition andMetabolism endorses
the use of the Malnutrition Screening Tool (MUST) (6, 7) and
the Nutritional Risk Screening (NRS-2002) (8) and the Mini
Nutritional Assessment (MNA)–Short Form for the elderly (9,
10). Some tools claim to have been developed to screen specific
target groups; however, there are currently no disease-specific
recommendations. There is no international consensus on a
single “best tool” to identify all 3 syndromes across populations.
The use of different tools in different studies makes drawing
any conclusions about their comparison and meta-analyses
difficult.
Current diagnostic methods for sarcopenia and cachexia
include the assessment of body anthropometric measures using
either BMI or estimated weight loss, or by direct assessment
of muscle and fat mass using dual-energy X-ray absorptiometry
(DXA), bioelectrical impedance analysis, computed tomography
(CT), or MRI scanning. Although the latter 2 radiographic
modalities are accurate, they are impractical and expensive
and some expose the patient to radiation. This diagnostic
approach to detect the presence of sarcopenia is time consuming,
expensive, and requires highly specialized equipment (11).
Therefore, a screening tool that is implementable in a larger
population that allows for early detection is important. This
approach would highlight the potential for further assessment
with early biomarkers, thus allowing prophylactic intervention
in malnutrition and driving further research in sarcopenia and
cachexia.
We aimed to systematically review validated screening tools
for the general adult population to enable clinicians to distinguish
between the 3 syndromes. The specific strengths and limitations
of each tool were assessed, as was the appropriateness of the
validation population. Through psychometric evaluation and
assessment of the tools against the agreed-upon consensus
definitions, we also investigated if any one single tool could be
used for the simultaneous assessment of all 3 syndrome.
METHODS
Methods for conducting systematic reviews of the effec-
tiveness of interventions have been well described. In accor-
dance with PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines (12), we applied the
principles to systematically reviewing validated screening tools
used in the assessment of cachexia, sarcopenia, and malnutrition.
Literature review
A systematic search was performed on 7 August 2018 in
Ovid Medline (1946–2017), EMBASE (1974–2017), CINAHL
(Cumulative index to Nursing and Allied Health Literature),
and Web of Science. Relevant articles were identified by title
and abstract. Reference lists of review articles were also hand-
searched. Double data extraction was performed by 2 reviewers
independently to ensure consistency. Any disagreements were
settled by a third reviewer.
The basic search strategy was “Sarcopenia” OR “Cachexia”
OR “Malnutrition” AND “screening” AND “validation study”
using MeSH (Medical Subject Heading) terms and keywords
appropriate to each database. No language restriction was
imposed. The search was designed to be broad to ensure all
validated tools were identified. A full copy of the search used
for Medline can be found in the Supplemental Material. There
were no disease-specific or language limits.
Inclusion and exclusion criteria
Studies were included if they had developed a screening tool
that had been validated for the screening of either cachexia,
sarcopenia, or malnutrition in adults (Table 1). Disease-specific
tools were included. Studies were excluded if the tools had not
been validated or if they assessed malnutrition in children or
obesity in adults. Studies that described modified versions of pre-
existing tools were also excluded because this was out of the
scope of this review. It was intended that studies that included
<25 patients should be excluded because they were unlikely
to yield robust, generalizable psychometric results; however, no
studies with numbers smaller than this were found.
Assessment of validity
Studies had to have evaluation of ≥2 of the following
psychometric characteristics: content validity, construct validity
(e.g., including convergent validity, discriminant validity), test-
retest reliability, internal consistency, responsiveness, factor
analysis, or criterion validity. Primary criteria used to evaluate
the tools were construct validity and responsiveness.
Criterion and construct validity, reference method
Studying the validity of a tool usually involves comparison to
a gold standard. Although many research groups are now using
cross-sectional imaging to investigate UWL, there is currently no
perfect gold standard. Studies used different reference methods
to validate their tools (e.g., DXA and assessment by a health
professional). The tools Subjective Global Assessment (SGA)
and the MNA are the tools currently recognized as the industry
standard and were therefore considered valid references. The
term “criterion validity” was used for these comparisons.
Less-valid reference methods, including the use of other
screening tools and blood tests (e.g., albumin) which can be
influenced by other factors including inflammation and acute
disease, were included because many research groups vary in
their opinion on the optimal reference method (13). These
comparisons were termed “construct validity.”
Predictive validity
Predictive validity was assessed as the ability of the tool to
predict the probability of a better or worse clinical outcome due
to nutritional risk.
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TABLE 1
Inclusion criteria
Description
Types of participants: adults (aged >18 y) undergoing routine screening
for cachexia, sarcopenia, or malnutrition
Includes patients with advanced cancer and end-stage cardiac, renal, and liver
disease
Types of tools: validated, quantitative measurements of cachexia,
sarcopenia or malnutrition
Tools developed for clinical or research purposes; completed by health care
professionals
Psychometric evaluation (demonstration of ≥2 criteria)
Content validity Breadth of scope of tool: to what extent does it appear to capture the relevant
aspects of unintentional weight loss; are there gaps?
Construct validity, including convergent validity, discriminant validity How well the tool relates to other measures of the same construct; lack of
correlation with dissimilar or unrelated constructs or variables
Test-retest reliability How consistent an individual’s scores are over a defined time period
presuming weight stays constant
Internal consistency How closely related are the different items in the tool?
Responsiveness Ability to detect clinically meaningful change for individuals
Factor analysis For a tool comprising several items, a way of grouping them into factors which
may tap into a particular construct
Criterion validity A shortened version of a scale, concurrent validity with the longer version that
has been validated
Diagnostic criteria
Tools were also assessed for their ability to identify the
risk of cachexia, sarcopenia, or malnutrition by comparison of
their components against the components of each set of chosen
diagnostic criteria (Table 2).
Assessment of bias
Assessment of bias was made with the use of a form of the
Newcastle-Ottawa scale adapted for cross-sectional studies (14).
Each study was scored out of 10 possible points, and a study with
a score of<5was considered to be at high risk of bias. Full details
of the scoring used can be found in the Supplemental Material.
Secondary criteria
Secondary criteria included face validity, development and
content validity, factor analysis, test-retest reliability, internal
consistency, and respondent and administrative burden (the time
and effort required to complete the tool). These are also summa-
rized in Table 1. Data were extracted on the study participants, the
tool used, and psychometric evaluations (inclusion criteria, Table
1). An assessment of sensitivity and specificity was made. A
value>80%was considered good, 60–80% fair, and<60% poor.
Agreement was also assessed as follows: 0.9–1.0 = excellent,
0.80–0.90 = good, 0.60–0.80 = fair, and <0.60 = poor.
RESULTS
Principal findings
Thirty-eight studies were included that described the valida-
tion of 22 screening tools. The majority of studies were excluded
because they described nonvalidated tools. This is summarized in
Figure 1.
The Cachexia score (CASCO) was the only screening tool
for cachexia that had been validated. It performed well against
diagnostic criteria (3), but sensitivities and specificities were not
recorded. Only 2 tools assessed sarcopenia [the Short Portable
Sarcopenia Measure (SPSM) and the SARC-F] and scored well
against the agreed definition (1). However, the SPSM required
a large amount of equipment and the SARC-F had very low
sensitivity. Both were validated for use in the outpatient setting.
TABLE 2
Summary of proposed diagnostic criteria for identification of cachexia, sarcopenia, and malnutrition1
Syndrome Diagnostic criteria
Cachexia Weight loss >5% or weight loss >2% in individuals already showing depletion according to current body weight and height [BMI
(in kg/m2) <20] or skeletal muscle mass (sarcopenia)2
Sarcopenia Loss of function: 6-min walk <400 m or gait speed <1.0 m/s
Muscle mass: low appendicular lean mass or height3 (2 SDs below the mean diagnostic on DXA4)
Malnutrition Protein-energy deficiency: risk indicated by low BMI <18.5 or weight loss >10% (indefinite time)/5% over last 3 mo and BMI
<20 (if aged <70 y)/<22 (if aged >70 y) or FFMI <15 and 17 kg/m2 in men and women, respectively5
1DXA, dual-energy X-ray absorptiometry; FFMI, fat-free mass index.
2Data from reference 3.
3Data from reference 2.
4Data from references 1 and 2.
5Data from reference 4.
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FIGURE 1 PRISMA flow diagram (12). PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Nineteen tools screened for malnutrition. The 3-Minute Nutrition
Score (3-MinNS) proved to be the best, scoring well against
the consensus definition (European Society for Clinical Nutrition
and Metabolism) as well as having sensitivities and specificities
>80%. There was no single validated tool that adequately
screened for all 3 conditions. A critical appraisal of all tools can
be found in Table 3.
Tools with evidence of validity, reliability, and acceptability
The available validity, reliability, and acceptability data are
summarized in Tables 4 and 5. Table 6 assesses how well
each tool encompasses the criteria in the chosen definitions.
Assessment of bias is shown in Table 7.
Sarcopenia
In total, 2 tools were found that were validated for the
assessment of sarcopenia (SPSM and SARC-F). Three other
tools assessed muscle function, but no other tools made an
assessment of muscle strength, mass, or wasting. Both tools that
were validated for the assessment of sarcopenia were done so in
the community setting. They agreed with the SCWD diagnostic
criteria, but the SARC-F showed variation in agreement against
the 3 consensus definitions it was validated against (EWGSOP,
IWGS criteria, and the Asian working group for sarcopenia). The
SARC-F had good specificity (94.2–99.1%) but poor sensitivity
(3.8–9.9%, dependent on sex) and also showed good agreement
(0.78–0.90). Values for the SPSM were not assessed.
Cachexia
Only 1 tool had been validated for the screening of cachexia—
the CASCO. Overall, 6 tools quantified weight loss within a
specified time frame, with a further 3 quantifying it within
an unspecified time frame. Sixteen tools characterized weight
loss as unintentional. Only 7 tools asked about the presence of
underlying disease, and only the CASCO took into account the
presence of elevated inflammatory markers and quality of life.
Sensitivities and specificities were not recorded for the CASCO,
but it scored well in the assessment of its validity, with it being
able to quantitatively classify stages of cachexia. Its ability to
predict patient outcome was not assessed.
Malnutrition
Nineteen screening tools were found to be validated for
the assessment of malnutrition. However, only 12 of these
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TABLE 3
Critical appraisal of tools to measure unintentional weight loss1
Study, year (ref) Tool Description Validation population Validation reference Strengths Limitations
Sarcopenia
Woo et al., 2014 (15) SARC-F A questionnaire regarding ability to carry
a heavy load, walking, rising from a
chair, climbing stairs, and frequency of
falls
Community-dwelling
Chinese (n = 4000)
3 consensus
definitions of
sarcopenia
Not dependent on cutoff
values
No assessment of muscle
mass, not validated in
hospital populations
Miller et al., 2009 (16) SPSM Portable measure that combines estimates
of muscle quantity and function into a
single scale
Community-dwelling
African Americans
(n = 998)
DXA Portable Time-consuming,
equipment-dependent,
muscle mass not measured
Cachexia
Argiles et al., 2017 (17) CASCO Score to classify cachectic patients into 3
different groups; includes 5
components: body weight loss and
composition, inflammation/metabolic
disturbances/immunosuppression,
physical performance, anorexia, and
quality of life
Cancer patients
(n = 186)
Assessment by
oncologist
Encompasses all
diagnostic criteria
Involves many questions and
measurements, does not
include questions on
disease state
Malnutrition
Weekes et al., 2004 (18) BAPEN Tool based on 4 nutritional parameters
(weight, height, recent UWL, and
appetite)
Acute medical and
elderly care wards
(n = 100)
Dietitian Quick and easy Percentage of weight loss
not quantified
Mimiran et al., 2011 (19) BNST Score based on UWL, unintentional
eating loss, and being unable to eat for
>5 d
Medical and surgical
(n = 446)
Dietitian Easily completed by
nursing staff
Low importance given to
amount of weight loss
Laporte et al., 2015 (20) CNST Tool containing 2 items: weight loss and
decreased food intake
Medical and surgical
(n = 150)
SGA Very brief, can be
completed by
nontrained rater
Assessed on admission only;
validity of rescreening
unknown
Ignacio et al., 2005 (21) CONUT Evaluates nutrition using albumin,
cholesterol, and lymphocyte count;
automated system
Medical and surgical
inpatients (n = 53)
SGA Simple, automated Markers vary depending on
disease state, only done in
patients who have blood
samples taken
Guerra et al., 2017 (22) EDC Screening tool based on ESPEN criteria
for diagnosis malnutrition
Medical and surgical
inpatients (n = 632)
PG-SGA Includes FFM
assessment
Very low sensitivity
Abd-El-Gawad et al., 2014 (23) GNRI Modified nutritional risk index for
geriatric patients (based on albumin,
current and previous weight)
Acute geriatrics ward
(n = 131)
MNA Good prognosticator,
does not require
capacity
Diseases associated with
high mortality or
hypoalbuminemia
excluded
Tammam et al., 2009 (24) INSYST Two-tiered tool: first is a simple
prescreen aiming to establish if
malnourished; second provides a more
detailed evaluation
Medical, surgical and
oncological inpatients
(n = 61)
MUST and MNA Does not require height
and BMI, quick and
easy
Ease of completing
dependent on patient’s
cognitive state
Ferguson et al., 1999 (25) MST Two questions regarding appetite and
UWL
Medical and surgical
inpatients (n = 408)
SGA Very quick, does not
require calculations
Nonspecific
Isenring et al., 2006 (26) Oncology outpatients
(n = 51)
PG-SGA
Neelemaat et al., 2011 (27) Acute hospitalized
(n = 193)
Malnutrition
definition
Nursal et al., 2005 (28) Medical and surgical
inpatients (n = 2211)
CT
Young et al., 2013 (29) Elderly medical
inpatients (n = 134)
—
Wu et al., 2012 (30) Elderly inpatients
(n = 157)
—
Bhuachalla et al., 2018 (31) Oncology patients
(n = 725)
—
Leiopold et al., 2018 (32) Rehabilitation patients
(n = 160)
—
Kim et al., 2011 (33) MSTC Tool based on intake change, weight loss,
ECOG performance status, and BMI
Oncology inpatients
(n = 1057)
PG-SGA Cancer-specific Designed to be performed by
dietitians, not nurses
Boleo-Tome et al., 2012 (34) MUST Five-step tool including BMI, unplanned
weight loss, and presence of acute
disease
Oncology inpatients
(n = 450)
PG-SGA Quick, easy Does not pick up patients
with normal BMI who are
malnourished, UWL
reported by patients is
subjective
Leistra et al., 2013 (35) Medical and surgical
outpatients (n= 2236)
Malnutrition
definition
Sharma et al., 2017 (36) Acute medical inpatients
(n = 132)
CT
Neelemaat et al., 2011 (27) Elderly inpatients
(n = 198)
—
Kyle et al., 2006 (37) Medical and surgical
(n = 995)
—
(Continued)
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TABLE 3
(Continued)
Study, year (ref) Tool Description Validation population Validation reference Strengths Limitations
Young et al., 2013 (29) Medical inpatients
(n = 134)
—
Almeida et al., 2012 (38) Surgical inpatients
(n = 300)
—
Velasco et al., 2011 (39) Medical and surgical
(n = 400)
—
Bhuachalla et al., 2018 (31) Oncology patients
(n = 725)
—
Prasad et al., 2012 (40) NRI Derived from serum albumin
concentration and ratio of usual to
present weight
Peritoneal dialysis
patients (n = 283)
SGA Assesses dialysis
patients at risk
Relies on previous weight;
limited use with changes
in fluid status
Faramarzi et al., 2013 (41) Colorectal cancer
(n = 52)
CT
Bhuachalla et al., 2018 (31) Oncology patients
(n = 725)
—
Neelemaat et al., 2011 (27) NRS-2002 Tool containing nutritional components
of the MUST along with disease
severity
Elderly inpatients
(n = 198)
Definition of
malnutrition
Includes disease
severity; therefore.
applicable in ITU
Ease of completing
dependent on patient’s
cognitive state
Kyle et al., 2006 (37) Medical and surgical
(n = 995)
—
Young et al., 2013 (29) Elderly medical patients
(n = 134)
SGA
Almeida et al., 2012 (38) Surgical inpatients
(n = 300)
—
Bauer et al., 2005 (42) Acute geriatrics ward
(n = 121)
—
Velasco et al., 2011 (39) Medical and surgical
(n = 400)
—
Soderhamn et al., 2002 (43) NUFFE Three-point ordinal scale with 15 items
assessing weight loss, dietary history,
appetite, and general activity
Elderly care rehab ward
(n = 114)
MNA Simple because lacks
anthropometric
measurements
Many confounding factors in
questionnaire
Duerksen et al., 2000 (44) SGA Assessment of nutritional status based on
history and examination
Acute elderly care and
elderly rehab (n = 95)
Geriatric and
internal medicine
resident, total
body nitrogen,
anthropometric
and biochemical
data
Current gold standard Reproducibility less than in
nonelderly, unable to
predict severe
malnutrition in ESRD,
requires experienced
operator to carry out
Cooper et al., 2002 (45) ESRD (n = 76) —
Moriana et al., 2014 (46) Medical and surgical
inpatients (n = 197)
—
Kruizenga et al., 2005 (47) SNAQ 26 questions related to eating and
drinking difficulties, defecation,
condition, and pain
Medical, surgical and
oncological inpatients
(n = 291)
Malnutrition
criteria, CONUT
Corresponds to ESPEN
criteria
High NPV, no outcome data
Leistra et al., 2013 (35) Medical and surgical
outpatients (n= 2236)
—
Harada et al., 2017 (48) Oncology outpatients
undergoing
chemotherapy
(n = 300)
—
Neelemaat et al., 2011 (27) Medical and surgical
inpatients (n = 2211)
—
Young et al., 2013 (29) Elderly medical
inpatients (n = 134)
—
Susetyowati et al., 2014 (49) SNST Six questions including weight loss,
appetite, and health status
Medical and surgical
inpatients (n = 495)
SGA Can be done by
nontrained staff
No anthropometric
assessment, all subjective
Wong et al., 2011 (50) Spinal NST Tool that assesses 8 criteria including
appetite, weight loss, and level of
spinal cord injury
Spinal cord injury
patients (n = 150)
Dietetic assessment Disease specific Requires specialized scales
to measure paralyzed
patients
Xia et al., 2016 (51) R-NST Nine questions assessing malnutrition
risk/symptoms combined with
albumin, CRP, and urea
Renal inpatients
(n = 122)
SGA Renal specific Patients picked up for
conditions other than
malnutrition (e.g.,
hyperkalemia)
Lim et al., 2009 (52) 3-MinNS Questionnaire based on diagnostic
criteria for malnutrition and muscle
wastage
Medical and surgical
inpatients (n = 818)
SGA Quick and easy Dependent on cognitive state
1BAPEN, British Association for Parenteral and Enteral Nutrition; BNST, British Nutrition Screening Tool; CASCO, Cachexia Score; CNST, Canadian Nutrition Screening Tool; CONUT, Controlling
Nutritional Status; CRP, C-reactive protein; CT, computed tomography; DXA, dual-energy X-ray absorptiometry; ECOG, ; EDC, ESPEN Diagnostic Criteria for Malnutrition; ESPEN, European Society for
Clinical Nutrition and Metabolism; ESRD, end-stage renal disease; FFM, fat-free mass; GNRI, Geriatric Nutrition Risk Index; INSYST, Imperial Nutritional Screening System; ITU, ; MNA, Mini Nutritional
Assessment; MST, Malnutrition Screening Tool; MSTC, Malnutrition Screening Tool for Cancer; MUST, Malnutrition Screening Tool; NPV, negative predictive value; NRI, Nutritional Risk Index; NRS-2002,
Nutritional Risk Screening; NUFFE, Nutritional Form for the Elderly; PG-SGA, ; ref, reference; R-NST, Renal Nutritional Screening Tool; SARC-F, ; SGA, Subjective Global Assessment; SNAQ, Short
Nutritional Assessment Questionnaire; Spinal NST, Spinal Nutritional Screening Tool; SPSM, Short Portable Sarcopenia Measure; UWL, unintentional weight loss; 3-MinNS, 3-Minute Nutrition Screening.
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TABLE 4
Psychometric evaluation of tools to measure unintentional weight loss1
Scale Environment
Context
(outpatients or
inpatients)
Face
validity
Content
validity
Factor
analysis
Construct
validity
Discriminant
validity
Predictive
validity Test-retest
Internal
consis-
tency Responsiveness Acceptability
Time to
complete
Sarcopenia
SARC-F Community dwelling Outpatients  − −  −  −  −  −
SPSM Community dwelling Outpatients − −  X      − 
Cachexia
CASCO Oncology Outpatients      − −   − −
Malnutrition
BAPEN Acute medical and
elderly care
Inpatients  − −  − −  −   
BNST Spinal cord injuries Inpatients  −  − − −  − − − −
CNST Medical and surgical Inpatients  − −  −   − − − −
CONUT Medical and surgical Inpatients  − X  − − − −   −
EDC Medical and surgical Inpatients  − − − −  −  − − −
GNRI Acute geriatrics Outpatients  −  − −  − − −  −
INSYST Medical, surgical, and
oncology
Inpatients   −  − −  −   
MST Medical, surgical, and
oncology
Inpatients,
outpatients
    −    −  −
MSTC Oncology Inpatients  X   − − − − − X 
MUST Medical, surgical, and
oncology
Inpatients,
outpatients
  X  −  − −   
NRI Peritoneal dialysis and
colorectal cancer
Inpatients − −  − −  − − −  −
NRS-2002 Elderly, medical, and
surgical
Inpatients   −  −   −   
NUFFE Elderly care rehab Inpatients,
outpatients
    −    − − −
R-NST Renal Inpatients     − − − − − X 
SGA Elderly, renal, medical,
and surgical
Inpatients     −    − − −
SNAQ Medical, surgical, and
oncology
Inpatients,
outpatients
  −     −   
SNST Medical and surgical Inpatients  −  −       
Spinal NST Spinal cord injuries Inpatients  −  − − −  − −  
3-MinNS Medical and surgical Inpatients   −     −   
1BAPEN, British Association for Parenteral and Enteral Nutrition; BNST, British Nutrition Screening Tool; CASCO, Cachexia Score; CNST, Canadian Nutrition Screening Tool; CONUT, Controlling
Nutritional Status; EDC, European Society for Clinical Nutrition and Metabolism Diagnostic Criteria for Malnutrition; GNRI, Geriatric Nutrition Risk Index; INSYST, Imperial Nutritional Screening System;
MST, Malnutrition Screening Tool; MSTC, Malnutrition Screening Tool for Cancer; MUST, Malnutrition Screening Tool; NRI, Nutritional Risk Index; NRS-2002, Nutritional Risk Screening; NUFFE,
Nutritional Form for the Elderly; R-NST, Renal Nutritional Screening Tool; SARC-F, ; SGA, Subjective Global Assessment; SNAQ, Short Nutritional Assessment Questionnaire; Spinal NST, Spinal Nutritional
Screening Tool; SPSM, Short Portable Sarcopenia Measure; 3-MinNS, 3-Minute Nutrition Screening; , tool assessed for and found to be valid; X, tool assessed for and found not to be valid; −, tool not
assessed for/not enough information provided.
incorporated a question about dietary intake or decline. Six
measured percentage weight loss over time, and 13 assessed
BMI. In particular, those tools that had high sensitivities and
specificities (Malnutrition Screening Tool for Cancer and Spinal
Nutrition Screening Tool) did not encompass all parts of the
agreed-upon definition. The Spinal Nutrition Screening Tool did
not assess BMI and the Malnutrition Screening Tool for Cancer
made no assessment of quantifying weight loss within a specified
time frame. The 3-MinNS was the tool that incorporated the
consensus definition criteria and also had high sensitivities and
specificities (>80%).
DISCUSSION
Overview
Although current systematic reviews have described the
results of studies examining malnutrition screening tools, to our
knowledge this is the first review to examine tools that have
been validated against another to assess cachexia, sarcopenia,
and malnutrition. There has only been one previous review
on tools for cachexia, sarcopenia, and malnutrition (53). This
review did not include psychometric evaluation, did not comment
on the validity of the tools, or compare them to the agreed-
upon consensus definitions. Existing systematic reviews of
malnutrition screening tools have been limited to describing tools
that are non–disease-specific and “quick and easy” or that have
been narrative in nature.
Thirty-eight studies describing 22 tools were identified and
judged for validity against a reference method. In the absence of a
generally recognized gold standard for screening, assessment by
a professional, DXA, CT, MRI, anthropometric measures, or the
screening tools SGA andMNAwere considered “valid” reference
methods by our research group (13, 44–46). Although cross-
sectional imaging is now used routinely for body-composition
analysis, only 3 tools identified were validated against CT. The
heterogeneity in populations, age groups, tools, and reference
methods was large, and therefore pooling of results was
impossible. Most tools had only been tested in one population,
making the drawing of any definitive conclusions difficult. There
were too few disease-specific tools to conclude which would be
superior for different disease processes.
Problems with current screening tools
For the generalized adult population, all of the tools showed
inconsistent results with regard to their validity. The SGA,
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TABLE 5
Sensitivity, specificity, predictive values, and reproducibility of the studies included1
Study, year (reference) Screening tool Sensitivity Specificity PPV NPV Agreement
Woo et al., 2014 (15) SARC-F 3.8–9.9 94.2–99.1 8.4–54.8 78.4–94.9 0.78–0.90
Miller et al., 2009 (16) SPSM — — — — —
Argiles et al., 2017 (17) CASCO — — — — —
Weekes et al., 2004 (18) BAPEN — — — — 0.77
Mirmiran et al., 2011 (19) BNST 86.7 61.7 79.1 73.1 0.74
Laporte et al., 2015 (20) CNST 72.6 85.1 81.2 77.0 0.88
Ignacio et al., 2005 (21) CONUT 92.3 85 — — 0.488
Guerra et al., 2017 (22) EDC 17.1 98.3 89.1 58.9 0.803
Abd-El-Gawad et al., 2014 (23) GNRI 83.1 51.2 78.95 58.33 0.713
Tammam et al., 2009 (24) INSYST 95–100 65–83 — — 0.73
Kim et al., 2011 (31) MST 93 93 98.4 72.7 0.7
Ferguson et al., 1999 (25) 100 92 80 100 0.83
Isenring et al., 2006 (26) 67 86 — — 0.53
Neelemaat et al., 2011 (27) 49 86 — — 0.33
Nursal et al., 2005 (28) 73 55 — — 0.28
Young et al., 2013 (29) 73 70 — — —
Wu et al., 2012 (30) 39 93 — — 0.21
Bhuachalla et al., 2018 (31) 39.4–100 47–74.6 — — 0.71
Leiopold et al., 2018 (32) 72.2 83.8 69.6 85.4 —
Kim et al., 2011 (33) MSTC 94 84.2 67.8 97.6 0.70
Boleotome et al., 2012 (34) MUST 80 89 100 100 —
Leistra et al., 2013 (35) 75 94 43 98 —
Sharma et al., 2017 (36) 69.7 75.8 75.4 70.1 0.49
Neelemaat et al., 2011 (27) 96 80 — — —
Kyle et al., 2006 (37) 61 79 — — —
Young et al., 2013 (29) 87 86 — — —
Almeida et al., 2012 (38) 85 93 — — —
Velasco et al, 2011 (39) 72 90 — — —
Bhuachalla et al., 2018 (31) 20.8–72.8 48–98.3 — — 0.816
Prasad et al., 2012 (40) NRI 92.9 32.39 80.41 60.53 0.63
Faramarzi et al., 2013 (41) 66 60 64 62 0.267
Bhuachalla et al., 2018 (31) 21.2–95 21.2–92.1 — — —
Neelemaat et al., 2011 (27) NRS-2002 92 85 — — —
Kyle et al., 2006 (37) 62 93 — — —
Young et al., 2013 (29) 90 83 — — —
Almeida et al., 2012 (38) 80 89 — — —
Bauer et al., 2005 (42) 70 85 — — —
Velasco et al., 2011 (39) 74 87 — — —
Soderhamn et al., 2002 (43) NUFFE 71 86 — — —
Xia et al., 2016 (51) R-NST 97.3 74.4 88.0 93.6 0.95
Duerksen et al., 2000 (44) SGA — — — — —
Cooper et al., 2002 (45) 59–68 61–65 41–42 70–83 0.6
Moriana et al., 2014 (46) — — — — —
Kruizenga et al., 2005 (47) SNAQ 79 83 70 89 —
Leistra et al., 2013 (35) 43 99 78 96 —
Harada et al., 2017 (48) 43 99 — — —
Neelemaat et al., 2011 (27) 75 84 — — —
Young et al., 2013 (29) 79 90 — — —
Susetyowati et al., 2014 (49) SNST 97 80 78 92 —
Wong et al., 2011 (50) Spinal NST 85.7 76.1 62 92 0.57
Lim et al., 2009 (52) 3-MinNS 86 83 67 94 —
1BAPEN, British Association for Parenteral and Enteral Nutrition; BNST, British Nutrition Screening Tool; CASCO, Cachexia Score; CNST, Canadian Nutrition Screening
Tool; CONUT, Controlling Nutritional Status; EDC, European Society for Clinical Nutrition and Metabolism Diagnostic Criteria for Malnutrition; GNRI, Geriatric Nutrition Risk
Index; INSYST, Imperial Nutritional Screening System; MST, Malnutrition Screening Tool; MSTC, Malnutrition Screening Tool for Cancer; MUST, Malnutrition Screening Tool;
NPV, negative predictive value; NRI, Nutritional Risk Index; NRS-2002, Nutritional Risk Screening; NUFFE, Nutritional Form for the Elderly; PPV, positive predictive value;
R-NST, Renal Nutritional Screening Tool; SARC-F, ; SGA, Subjective Global Assessment; SNAQ, Short Nutritional Assessment Questionnaire; SNST, ; Spinal NST, Spinal
Nutritional Screening Tool; SPSM, Short Portable Sarcopenia Measure; 3-MinNS, 3-Minute Nutrition Screening.
which is often considered to be the industry standard (54) and
against which many tools are validated, has not itself been
well validated. It performed well against the diagnostic criteria
but sensitivities and specificities were either not recorded or
poor. Arguably, the most well-known tools—MUST and NRS-
2002—showed a variation in results from poor to good (27,
29, 34–39, 42), and consistency between groups in which the
tools were studied was poor. The less well-known Nutritional
Form for the Elderly (NUFFE) showed good validity, but it has
been described in only a small portion of the literature and is
not implemented widely (43). The “quick and easy” screening
tools, including the Short Nutritional Assessment Questionnaire
and Malnutrition Screening Tool, performed reasonably well
(sensitivities of ∼80%) in most studies in which they were used
(25–30, 35, 47, 48). Of note because these tools are quick,
they require a further detailed assessment by a qualified health
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professional if screening is positive. They also miss ∼20% of at-
risk patients at initial screening and therefore may be more useful
in screening high-risk patients.
The tool that performed the best for malnutrition was the 3-
MinNS (52). It showed high sensitivity and specificity (>80%)
and accurately encompassed the correct diagnostic criteria
(percentage of weight loss over a specified time andmeasurement
of BMI) for malnutrition. It was validated in acute medical
and surgical patients and proved quick and easy to complete.
It has only been validated in one study, and therefore it cannot
be assumed that it would perform as well in different patient
populations. Both tools that assessed sarcopenia (SPSM, SARC-
F) scored well against the agreed-upon definition (15, 16).
However, the SPSM required transport of equipment and the
SARC-F had a very low sensitivity (13, 15). The CASCO was
the only validated screening tool for cachexia (17). It performed
well against diagnostic criteria, but sensitivities and specificities
were not recorded. It has also only been validated in the cancer
setting; more work would be needed to validate the tool in other
cachectic populations or the general adult population.
Most tools were validated in the adult hospital inpatient
setting. Tools for sarcopenia have only been validated in healthy,
community-dwelling elderly individuals (15, 16). Length of
hospital stay is diminishing worldwide, and outpatient nutritional
screening is advocated to detect patients at risk. In this review,
we identified 8 studies in which outpatients were included. More
studies focusing on the construct and predictive validity of tools
for outpatient screening are warranted, especially because care is
shifting to this setting.
The tool that appeared to have the broadest coverage was the
CASCO (17). It is the only tool that screens for cachexia but
also detects many of the variables required for a diagnosis of
malnutrition. However, assessment of muscle mass or function
(required for sarcopenia) is not included. One previous review
showed that 20 screening tools appeared to be relevant for
starvation, but none contained all of the currently accepted
components needed to screen for sarcopenia and cachexia risk
(53). Our study supports this finding.
Outlook and recommendations for future tools
A screening tool needs to be developed that encompasses
the criteria to detect all 3 possible syndromes. This concept is
supported by the notion that, in humans, there may be no “pure”
phenotype of cachexia, because it is usually associated with
reduced food intake (potential for malnutrition) and increasing
age (increasing sarcopenia) (55). There is also currently a lack of
agreement as to the diagnostic criteria for each syndrome and the
relative importance of body-composition analysis and the nature
of depleted tissue within each definition. We hypothesized that
the overlap between syndromes could be shown, as in Figure 2,
along with the identified best-performing tools for each aspect.
There are clearly many existing validated screening tools (at
least for malnutrition). It is unlikely that any further novel tools
will be devisedwithout breakthroughs in biomarker development.
We therefore suggest that the ideal composite tool should
incorporate a stepwise assessment of nutritional status—oral
intake, disease status, patient age, muscle mass and function,
and metabolic derangement. The presence of underlying disease
FIGURE 2 Diagram to show overlap between cachexia, sarcopenia, and
malnutrition. The sizes of the circles represent the perceived sizes of each
clinical problem. CASCO, Cachexia Score; SARC-F, ; SPSM, Short Portable
Sarcopenia Measure; 3-MinNS, 3-Minute Nutrition Score.
is a key question in order to stratify the syndromes. Suggested
components for use in creating a new tool are depicted inTable 8.
The use of screening for all 3 syndromes will allow for a
more targeted intervention. Screening for cachexia, sarcopenia,
or malnutrition is not warranted unless it is accompanied by an
intervening care plan. It would be expected that an adequate
intervention would prevent any further decline in health status
and therefore lead to a positive effect on disease outcome. Most
studies did not comment on intervention, which, depending on the
balance of the 3 syndromes,may need to include varying attention
to nutrition, exercise, and measures to combat inflammation.
Strengths, limitations, and assessment of bias
One of the strengths of this review is that it provides a
complete overview of tools that have been validated for cachexia,
sarcopenia, and malnutrition. We did not describe reliability,
repeatability, or other clinical outcome measures in any great
detail. The review used the consensus definitions of each
syndrome. We are aware, however, that many other definitions
exist. However, there were a number of study limitations. There
was a risk of bias when assessing each tool for their predictive
validity. Studies may have been biased if they did not adjust
for factors such as cancer stage or disease severity. Because
TABLE 8
Suggested components for use in creating a new screening tool
1. Quantification of weight loss
2. Measurement of BMI
3. Assessment of appetite/dietary intake and decline
4. Underlying health state: Is there the presence of chronic disease?
5. Take into account patient’s age (i.e., age >60 y more likely to be
sarcopenic)
6. Assessment of muscle mass and function
7. Measurement of metabolic derangement/increased C-reactive protein
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clinical outcome is affected by more than just nutritional status
alone, adjusting for these variables is important. Nutritional
intervention is likely to improve outcomes for malnutrition, but
potentially not for age-related sarcopenia or established cachexia.
Only one study discussed whether they did this. There is no
agreed-upon “gold standard” tool, and therefore we chose cross-
sectional imaging and the SGA and MNA on the basis of the
results of previous studies (13). Tools that were compared with
potentially less-valid standards were also included to allow a
wider analysis. Full nutrition assessments were different in each
study, ranging from anthropometric to biochemical measures and
full assessment by a medical professional. Conclusions from
this review were based on the original studies in which there
may have been varying definitions with regard to the subject
group, syndrome, or assessment undertaken. Another potential
limitation is that we excluded modified versions of pre-existing
tools. They were excluded because reliability and validity data
would only relate to themodified tool and it was therefore difficult
to assess improvements from the original. It is possible that these
tools were being improved or evaluated more thoroughly.
Conclusions
We have highlighted that many practitioners who regularly
come into contact with patients suffering fromweight loss are not
able to easily screen between the conditions of cachexia, sarcope-
nia, and malnutrition because there is no single validated tool that
can be implemented for the assessment of all 3 conditions. The
adaptation of existing screening tools incorporating all relevant
criteria described in this review would be optimal for diagnosis
and to direct the content of complex interventions.
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